keyword
MENU ▼
Read by QxMD icon Read
search

tickoo

keyword
https://www.readbyqxmd.com/read/28368923/reporting-and-staging-of-testicular-germ-cell-tumors-the-international-society-of-urological-pathology-isup-testicular-cancer-consultation-conference-recommendations
#1
Clare Verrill, Asli Yilmaz, John R Srigley, Mahul B Amin, Eva Compérat, Lars Egevad, Thomas M Ulbright, Satish K Tickoo, Daniel M Berney, Jonathan I Epstein
The International Society of Urological Pathology held a conference devoted to issues in testicular and penile pathology in Boston in March 2015, which included a presentation and discussion led by the testis microscopic features working group. This conference focused on controversies related to staging and reporting of testicular tumors and was preceded by an online survey of the International Society of Urological Pathology members. The survey results were used to initiate discussions, but decisions were made by expert consensus rather than voting...
March 31, 2017: American Journal of Surgical Pathology
https://www.readbyqxmd.com/read/28329682/the-swi-snf-protein-pbrm1-restrains-vhl-loss-driven-clear-cell-renal-cell-carcinoma
#2
Amrita M Nargund, Can G Pham, Yiyu Dong, Patricia I Wang, Hatice U Osmangeyoglu, Yuchen Xie, Omer Aras, Song Han, Toshinao Oyama, Shugaku Takeda, Chelsea E Ray, Zhenghong Dong, Mathieu Berge, A Ari Hakimi, Sebastien Monette, Carl L Lekaye, Jason A Koutcher, Christina S Leslie, Chad J Creighton, Nils Weinhold, William Lee, Satish K Tickoo, Zhong Wang, Emily H Cheng, James J Hsieh
PBRM1 is the second most commonly mutated gene after VHL in clear cell renal cell carcinoma (ccRCC). However, the biological consequences of PBRM1 mutations for kidney tumorigenesis are unknown. Here, we find that kidney-specific deletion of Vhl and Pbrm1, but not either gene alone, results in bilateral, multifocal, transplantable clear cell kidney cancers. PBRM1 loss amplified the transcriptional outputs of HIF1 and STAT3 incurred by Vhl deficiency. Analysis of mouse and human ccRCC revealed convergence on mTOR activation, representing the third driver event after genetic inactivation of VHL and PBRM1...
March 21, 2017: Cell Reports
https://www.readbyqxmd.com/read/28296677/rbm10-tfe3-renal-cell-carcinoma-a-potential-diagnostic-pitfall-due-to-cryptic-intrachromosomal-xp11-2-inversion-resulting-in-false-negative-tfe3-fish
#3
MULTICENTER STUDY
Pedram Argani, Lei Zhang, Victor E Reuter, Satish K Tickoo, Cristina R Antonescu
Xp11 translocation renal cell carcinoma (RCC) are defined by chromosome translocations involving the Xp11 breakpoint which results in one of a variety of TFE3 gene fusions. TFE3 break-apart florescence in situ hybridization (FISH) assays are generally preferred to TFE3 immunohistochemistry (IHC) as a means of confirming the diagnosis in archival material, as FISH is less sensitive to the variable fixation which can result in false positive or false negative IHC. Prompted by a case report in the cytogenetics literature, we identify 3 cases of Xp11 translocation RCC characterized by a subtle chromosomal inversion involving the short arm of the X chromosome, resulting in an RBM10-TFE3 gene fusion...
May 2017: American Journal of Surgical Pathology
https://www.readbyqxmd.com/read/28162629/-386-the-influence-of-age-and-gender-on-opioid-dosage-in-cancer-pain-clinic-patients
#4
N Moryl, V Dave, P Glare, V Malhotra, A Gulati, J Hung, V Puttanniah, Y Griffo, R Tickoo, A Wiesenthal, C Johnson, S Horn, C Inturrisi
No abstract text is available yet for this article.
April 2016: Journal of Pain: Official Journal of the American Pain Society
https://www.readbyqxmd.com/read/28095036/differentiation-of-clear-cell-renal-cell-carcinoma-from-other-renal-cortical-tumors-by-use-of-a-quantitative-multiparametric-mri-approach
#5
Andreas M Hötker, Yousef Mazaheri, Andreas Wibmer, Christoph A Karlo, Junting Zheng, Chaya S Moskowitz, Satish K Tickoo, Paul Russo, Hedvig Hricak, Oguz Akin
OBJECTIVE: The purpose of this study was to develop a quantitative multiparametric MRI approach to differentiating clear cell renal cell carcinoma (RCC) from other renal cortical tumors. MATERIALS AND METHODS: This retrospective study included 119 patients with 124 histopathologically confirmed renal cortical tumors who underwent preoperative MRI including DWI, contrast-enhanced, and chemical-shift sequences before nephrectomy. Two radiologists independently assessed each tumor volumetrically, and apparent diffusion coefficient values, parameters from multiphasic contrast-enhanced MRI (peak enhancement, upslope, downslope, AUC), and chemical-shift indexes were calculated...
March 2017: AJR. American Journal of Roentgenology
https://www.readbyqxmd.com/read/27801954/the-world-health-organization-2016-classification-of-testicular-non-germ-cell-tumours-a-review-and-update-from-the-international-society-of-urological-pathology-testis-consultation-panel
#6
REVIEW
Muhammad T Idrees, Thomas M Ulbright, Esther Oliva, Robert H Young, Rodolfo Montironi, Lars Egevad, Daniel Berney, John R Srigley, Jonathan I Epstein, Satish K Tickoo
The World Health Organization (WHO) released a new tumour classification for the genitourinary system in early 2016 after consensus by pathologists with expertise in these organs. It utilized the framework of the 2004 classification, and incorporated the most up-to-date information concerning these tumours. In testicular tumours, the majority of the changes occurred in the nomenclature and classification of germ cell tumours; however, several modifications were also made for non-germ cell tumours. Among sex cord-stromal tumours, sclerosing Sertoli cell tumour (SCT) is no longer recognized as a separate entity but as a morphological variant of SCT not otherwise specified (NOS), as CTNNB1 gene mutations have been noted in both neoplasms but not in the other forms of SCT...
March 2017: Histopathology
https://www.readbyqxmd.com/read/27747907/the-world-health-organization-2016-classification-of-testicular-germ-cell-tumours-a-review-and-update-from-the-international-society-of-urological-pathology-testis-consultation-panel
#7
REVIEW
Sean R Williamson, Brett Delahunt, Cristina Magi-Galluzzi, Ferran Algaba, Lars Egevad, Thomas M Ulbright, Satish K Tickoo, John R Srigley, Jonathan I Epstein, Daniel M Berney
Since the last World Health Organization (WHO) classification scheme for tumours of the urinary tract and male genital organs, there have been a number of advances in the understanding, classification, immunohistochemistry and genetics of testicular germ cell tumours. The updated 2016 draft classification was discussed at an International Society of Urological Pathology Consultation on Testicular and Penile Cancer. This review addresses the main updates to germ cell tumour classification. Major changes include a pathogenetically derived classification using germ cell neoplasia in situ (GCNIS) as a new name for the precursor lesion, and the distinction of prepubertal tumours (non-GCNIS-derived) from postpubertal-type tumours (GCNIS-derived), acknowledging the existence of rare benign prepubertal-type teratomas in the postpubertal testis...
February 2017: Histopathology
https://www.readbyqxmd.com/read/27713405/molecular-analysis-of-aggressive-renal-cell-carcinoma-with-unclassified-histology-reveals-distinct-subsets
#8
Ying-Bei Chen, Jianing Xu, Anders Jacobsen Skanderup, Yiyu Dong, A Rose Brannon, Lu Wang, Helen H Won, Patricia I Wang, Gouri J Nanjangud, Achim A Jungbluth, Wei Li, Virginia Ojeda, A Ari Hakimi, Martin H Voss, Nikolaus Schultz, Robert J Motzer, Paul Russo, Emily H Cheng, Filippo G Giancotti, William Lee, Michael F Berger, Satish K Tickoo, Victor E Reuter, James J Hsieh
Renal cell carcinomas with unclassified histology (uRCC) constitute a significant portion of aggressive non-clear cell renal cell carcinomas that have no standard therapy. The oncogenic drivers in these tumours are unknown. Here we perform a molecular analysis of 62 high-grade primary uRCC, incorporating targeted cancer gene sequencing, RNA sequencing, single-nucleotide polymorphism array, fluorescence in situ hybridization, immunohistochemistry and cell-based assays. We identify recurrent somatic mutations in 29 genes, including NF2 (18%), SETD2 (18%), BAP1 (13%), KMT2C (10%) and MTOR (8%)...
October 7, 2016: Nature Communications
https://www.readbyqxmd.com/read/27635946/tubulocystic-carcinoma-of-the-kidney-with-poorly-differentiated-foci-a-frequent-morphologic-pattern-of-fumarate-hydratase-deficient-renal-cell-carcinoma
#9
Steven C Smith, Kiril Trpkov, Ying-Bei Chen, Rohit Mehra, Deepika Sirohi, Chisato Ohe, Andi K Cani, Daniel H Hovelson, Kei Omata, Jonathan B McHugh, Wolfram Jochum, Maurizio Colecchia, Mitual Amin, Mukul K Divatia, Ondřej Hes, Santosh Menon, Isabela Werneck da Cunha, Sergio Tripodi, Fadi Brimo, Anthony J Gill, Adeboye O Osunkoya, Cristina Magi-Galluzzi, Mathilde Sibony, Sean R Williamson, Gabriella Nesi, Maria M Picken, Fiona Maclean, Abbas Agaimy, Liang Cheng, Jonathan I Epstein, Victor E Reuter, Satish K Tickoo, Scott A Tomlins, Mahul B Amin
An emerging group of high-grade renal cell carcinomas (RCCs), particularly carcinomas arising in the hereditary leiomyomatosis renal cell carcinoma syndrome (HLRCC), show fumarate hydratase (FH) gene mutation and loss of function. On the basis of similar cytomorphology and clinicopathologic features between these tumors and cases described as tubulocystic carcinomas with poorly differentiated foci (TC-PD) of infiltrative adenocarcinoma, we hypothesized a relationship between these entities. First, 29 RCCs with morphology of TC-PD were identified retrospectively and assessed for FH expression and aberrant succination (2SC) by immunohistochemistry (IHC), with targeted next-generation sequencing of 409 genes-including FH-performed on a subset...
November 2016: American Journal of Surgical Pathology
https://www.readbyqxmd.com/read/27601542/phase-ii-trial-and-correlative-genomic-analysis-of-everolimus-plus-bevacizumab-in-advanced-non-clear-cell-renal-cell-carcinoma
#10
Martin H Voss, Ana M Molina, Ying-Bei Chen, Kaitlin M Woo, Joshua L Chaim, Devyn T Coskey, Almedina Redzematovic, Patricia Wang, William Lee, S Duygu Selcuklu, Chung-Han Lee, Michael F Berger, Satish K Tickoo, Victor E Reuter, Sujata Patil, James J Hsieh, Robert J Motzer, Darren R Feldman
PURPOSE: The decreased effectiveness of single-agent targeted therapies in advanced non-clear cell renal cell carcinoma (ncRCC) compared with clear cell renal cell carcinoma (RCC) supports the study of combination regimens. We evaluated the efficacy of everolimus plus bevacizumab in patients with metastatic ncRCC. PATIENTS AND METHODS: In this single-center phase II trial, treatment-naive patients received everolimus 10 mg oral once per day plus bevacizumab 10 mg/kg intravenously every 2 weeks...
September 6, 2016: Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology
https://www.readbyqxmd.com/read/27438987/the-2014-fred-w-stewart-award-thomas-m-ulbright-md
#11
Victor E Reuter, Satish K Tickoo
No abstract text is available yet for this article.
July 19, 2016: American Journal of Surgical Pathology
https://www.readbyqxmd.com/read/27016623/renal-cell-carcinoma-a-nomogram-for-the-ct-imaging-inclusive-prediction-of-indolent-non-clear-cell-renal-cortical-tumours
#12
Christoph A Karlo, Lei Kou, Pier Luigi Di Paolo, Michael W Kattan, Robert J Motzer, Paul Russo, Satish K Tickoo, Oguz Akin, Hedvig Hricak
AIM: To develop a nomogram from clinical and computed tomography (CT) data for pre-treatment identification of indolent renal cortical tumours. PATIENTS AND METHODS: A total of 1201 consecutive patients underwent dedicated contrast-enhanced CT prior to nephrectomy for a renal cortical tumour between January 2000 and July 2011. Two radiologists evaluated all tumours on CT for size, necrosis, calcification, contour, renal vein invasion, collecting system invasion, contact with renal sinus fat, multicystic tumour architecture, nodular enhancement, and the degree of nephrographic phase enhancement...
May 2016: European Journal of Cancer
https://www.readbyqxmd.com/read/26901439/mitochondrial-dna-copy-number-variation-across-human-cancers
#13
Ed Reznik, Martin L Miller, Yasin Şenbabaoğlu, Nadeem Riaz, Judy Sarungbam, Satish K Tickoo, Hikmat A Al-Ahmadie, William Lee, Venkatraman E Seshan, A Ari Hakimi, Chris Sander
Mutations, deletions, and changes in copy number of mitochondrial DNA (mtDNA), are observed throughout cancers. Here, we survey mtDNA copy number variation across 22 tumor types profiled by The Cancer Genome Atlas project. We observe a tendency for some cancers, especially of the bladder, breast, and kidney, to be depleted of mtDNA, relative to matched normal tissue. Analysis of genetic context reveals an association between incidence of several somatic alterations, including IDH1 mutations in gliomas, and mtDNA content...
February 22, 2016: ELife
https://www.readbyqxmd.com/read/26901067/frequent-somatic-cdh1-loss-of-function-mutations-in-plasmacytoid-variant-bladder-cancer
#14
Hikmat A Al-Ahmadie, Gopa Iyer, Byron H Lee, Sasinya N Scott, Rohit Mehra, Aditya Bagrodia, Emmet J Jordan, Sizhi Paul Gao, Ricardo Ramirez, Eugene K Cha, Neil B Desai, Emily C Zabor, Irina Ostrovnaya, Anuradha Gopalan, Ying-Bei Chen, Samson W Fine, Satish K Tickoo, Anupama Gandhi, Joseph Hreiki, Agnès Viale, Maria E Arcila, Guido Dalbagni, Jonathan E Rosenberg, Bernard H Bochner, Dean F Bajorin, Michael F Berger, Victor E Reuter, Barry S Taylor, David B Solit
Plasmacytoid bladder cancer is an aggressive histologic variant with a high risk of disease-specific mortality. Using whole-exome and targeted sequencing, we find that truncating somatic alterations in the CDH1 gene occur in 84% of plasmacytoid carcinomas and are specific to this histologic variant. Consistent with the aggressive clinical behavior of plasmacytoid carcinomas, which frequently recur locally, CRISPR/Cas9-mediated knockout of CDH1 in bladder cancer cells enhanced cell migration.
April 2016: Nature Genetics
https://www.readbyqxmd.com/read/26766592/an-integrated-metabolic-atlas-of-clear-cell-renal-cell-carcinoma
#15
A Ari Hakimi, Ed Reznik, Chung-Han Lee, Chad J Creighton, A Rose Brannon, Augustin Luna, B Arman Aksoy, Eric Minwei Liu, Ronglai Shen, William Lee, Yang Chen, Steve M Stirdivant, Paul Russo, Ying-Bei Chen, Satish K Tickoo, Victor E Reuter, Emily H Cheng, Chris Sander, James J Hsieh
Dysregulated metabolism is a hallmark of cancer, manifested through alterations in metabolites. We performed metabolomic profiling on 138 matched clear cell renal cell carcinoma (ccRCC)/normal tissue pairs and found that ccRCC is characterized by broad shifts in central carbon metabolism, one-carbon metabolism, and antioxidant response. Tumor progression and metastasis were associated with metabolite increases in glutathione and cysteine/methionine metabolism pathways. We develop an analytic pipeline and visualization tool (metabolograms) to bridge the gap between TCGA transcriptomic profiling and our metabolomic data, which enables us to assemble an integrated pathway-level metabolic atlas and to demonstrate discordance between transcriptome and metabolome...
January 11, 2016: Cancer Cell
https://www.readbyqxmd.com/read/26700340/use-of-dwi-in-the-differentiation-of-renal-cortical-tumors
#16
Andreas M Hötker, Yousef Mazaheri, Andreas Wibmer, Junting Zheng, Chaya S Moskowitz, Satish K Tickoo, Paul Russo, Hedvig Hricak, Oguz Akin
OBJECTIVE: The purpose of this study was to differentiate clear cell renal cell carcinoma (RCC) from other common renal cortical tumors by use of DWI. MATERIALS AND METHODS: The study included 117 patients (mean age, 60 years) with 122 histopathologically confirmed renal cortical tumors who underwent 1.5-T MRI that included DWI before they underwent nephrectomy between 2006 and 2013. For each tumor, two radiologists independently evaluated apparent diffusion coefficient (ADC) values on the basis of a single ROI in a nonnecrotic area of the tumor and also by assessment of the whole tumor...
January 2016: AJR. American Journal of Roentgenology
https://www.readbyqxmd.com/read/26651452/relation-between-hospital-length-of-stay-and-quality-of-care-in-patients-with-acute-coronary-syndromes-from-the-american-heart-association-s-get-with-the-guidelines-coronary-artery-disease-data-set
#17
MULTICENTER STUDY
Sumit Tickoo, Adarsh Bhardwaj, Gregg C Fonarow, Li Liang, Deepak L Bhatt, Christopher P Cannon
Worries regarding short length of stay (LOS) adversely impacting quality of care prompted us to assess the relation between hospital LOS and inpatient guideline adherence in patients with acute coronary syndrome. We used the American Heart Association's Get with The Guidelines (GWTG)--Coronary Artery Disease data set. Data were collected from January 2, 2000, to March 21, 2010, for patients with acute coronary syndrome from 405 different sites. Of the 119,398 patients in the study, the mean LOS was 5.5 days with a median of 4 days...
January 15, 2016: American Journal of Cardiology
https://www.readbyqxmd.com/read/26536169/comprehensive-molecular-characterization-of-papillary-renal-cell-carcinoma
#18
W Marston Linehan, Paul T Spellman, Christopher J Ricketts, Chad J Creighton, Suzanne S Fei, Caleb Davis, David A Wheeler, Bradley A Murray, Laura Schmidt, Cathy D Vocke, Myron Peto, Abu Amar M Al Mamun, Eve Shinbrot, Anurag Sethi, Samira Brooks, W Kimryn Rathmell, Angela N Brooks, Katherine A Hoadley, A Gordon Robertson, Denise Brooks, Reanne Bowlby, Sara Sadeghi, Hui Shen, Daniel J Weisenberger, Moiz Bootwalla, Stephen B Baylin, Peter W Laird, Andrew D Cherniack, Gordon Saksena, Scott Haake, Jun Li, Han Liang, Yiling Lu, Gordon B Mills, Rehan Akbani, Mark D M Leiserson, Benjamin J Raphael, Pavana Anur, Donald Bottaro, Laurence Albiges, Nandita Barnabas, Toni K Choueiri, Bogdan Czerniak, Andrew K Godwin, A Ari Hakimi, Thai H Ho, James Hsieh, Michael Ittmann, William Y Kim, Bhavani Krishnan, Maria J Merino, Kenna R Mills Shaw, Victor E Reuter, Ed Reznik, Carl S Shelley, Brian Shuch, Sabina Signoretti, Ramaprasad Srinivasan, Pheroze Tamboli, George Thomas, Satish Tickoo, Kenneth Burnett, Daniel Crain, Johanna Gardner, Kevin Lau, David Mallery, Scott Morris, Joseph D Paulauskis, Robert J Penny, Candace Shelton, W Troy Shelton, Mark Sherman, Eric Thompson, Peggy Yena, Melissa T Avedon, Jay Bowen, Julie M Gastier-Foster, Mark Gerken, Kristen M Leraas, Tara M Lichtenberg, Nilsa C Ramirez, Tracie Santos, Lisa Wise, Erik Zmuda, John A Demchok, Ina Felau, Carolyn M Hutter, Margi Sheth, Heidi J Sofia, Roy Tarnuzzer, Zhining Wang, Liming Yang, Jean C Zenklusen, Jiashan Zhang, Brenda Ayala, Julien Baboud, Sudha Chudamani, Jia Liu, Laxmi Lolla, Rashi Naresh, Todd Pihl, Qiang Sun, Yunhu Wan, Ye Wu, Adrian Ally, Miruna Balasundaram, Saianand Balu, Rameen Beroukhim, Tom Bodenheimer, Christian Buhay, Yaron S N Butterfield, Rebecca Carlsen, Scott L Carter, Hsu Chao, Eric Chuah, Amanda Clarke, Kyle R Covington, Mahmoud Dahdouli, Ninad Dewal, Noreen Dhalla, Harsha V Doddapaneni, Jennifer A Drummond, Stacey B Gabriel, Richard A Gibbs, Ranabir Guin, Walker Hale, Alicia Hawes, D Neil Hayes, Robert A Holt, Alan P Hoyle, Stuart R Jefferys, Steven J M Jones, Corbin D Jones, Divya Kalra, Christie Kovar, Lora Lewis, Jie Li, Yussanne Ma, Marco A Marra, Michael Mayo, Shaowu Meng, Matthew Meyerson, Piotr A Mieczkowski, Richard A Moore, Donna Morton, Lisle E Mose, Andrew J Mungall, Donna Muzny, Joel S Parker, Charles M Perou, Jeffrey Roach, Jacqueline E Schein, Steven E Schumacher, Yan Shi, Janae V Simons, Payal Sipahimalani, Tara Skelly, Matthew G Soloway, Carrie Sougnez, Angela Tam, Donghui Tan, Nina Thiessen, Umadevi Veluvolu, Min Wang, Matthew D Wilkerson, Tina Wong, Junyuan Wu, Liu Xi, Jane Zhou, Jason Bedford, Fengju Chen, Yao Fu, Mark Gerstein, David Haussler, Katayoon Kasaian, Phillip Lai, Shiyun Ling, Amie Radenbaugh, David Van Den Berg, John N Weinstein, Jingchun Zhu, Monique Albert, Iakovina Alexopoulou, Jeremiah J Andersen, J Todd Auman, John Bartlett, Sheldon Bastacky, Julie Bergsten, Michael L Blute, Lori Boice, Roni J Bollag, Jeff Boyd, Erik Castle, Ying-Bei Chen, John C Cheville, Erin Curley, Benjamin Davies, April DeVolk, Rajiv Dhir, Laura Dike, John Eckman, Jay Engel, Jodi Harr, Ronald Hrebinko, Mei Huang, Lori Huelsenbeck-Dill, Mary Iacocca, Bruce Jacobs, Michael Lobis, Jodi K Maranchie, Scott McMeekin, Jerome Myers, Joel Nelson, Jeremy Parfitt, Anil Parwani, Nicholas Petrelli, Brenda Rabeno, Somak Roy, Andrew L Salner, Joel Slaton, Melissa Stanton, R Houston Thompson, Leigh Thorne, Kelinda Tucker, Paul M Weinberger, Cynthia Winemiller, Leigh Anne Zach, Rosemary Zuna
BACKGROUND: Papillary renal-cell carcinoma, which accounts for 15 to 20% of renal-cell carcinomas, is a heterogeneous disease that consists of various types of renal cancer, including tumors with indolent, multifocal presentation and solitary tumors with an aggressive, highly lethal phenotype. Little is known about the genetic basis of sporadic papillary renal-cell carcinoma, and no effective forms of therapy for advanced disease exist. METHODS: We performed comprehensive molecular characterization of 161 primary papillary renal-cell carcinomas, using whole-exome sequencing, copy-number analysis, messenger RNA and microRNA sequencing, DNA-methylation analysis, and proteomic analysis...
January 14, 2016: New England Journal of Medicine
https://www.readbyqxmd.com/read/25676555/tceb1-mutated-renal-cell-carcinoma-a-distinct-genomic-and-morphological-subtype
#19
A Ari Hakimi, Satish K Tickoo, Anders Jacobsen, Judy Sarungbam, John P Sfakianos, Yusuke Sato, Teppei Morikawa, Haruki Kume, Masashi Fukayama, Yukio Homma, Ying-Bei Chen, Alexander I Sankin, Roy Mano, Jonathan A Coleman, Paul Russo, Seishi Ogawa, Chris Sander, James J Hsieh, Victor E Reuter
Integrated sequencing analysis identified a group of tumors among clear cell renal cell carcinomas characterized by hotspot mutations in TCEB1 (a gene that contributes to the VHL complex to ubiquitinate hypoxia-inducible factor). We analyzed 11 tumors from two distinct cohorts with TCEB1 mutations along with an expanded cohort to assess whether these should be considered an entity distinct from clear cell renal cell carcinoma and clear cell papillary renal cell carcinoma. All tumors were characterized by hotspot mutations in TCEB1 Y79C/S/F/N or A100P...
June 2015: Modern Pathology: An Official Journal of the United States and Canadian Academy of Pathology, Inc
https://www.readbyqxmd.com/read/25676433/pathological-stage-t3a-significantly-increases-disease-recurrence-across-all-tumor-sizes-in-renal-cell-carcinoma
#20
Michael Chevinsky, Mariam Imnadze, Alexander Sankin, Andrew Winer, Roy Mano, Christopher Jakubowski, Joseph Mashni, Daniel D Sjoberg, Ying-Bei Chen, Satish K Tickoo, Victor E Reuter, A Ari Hakimi, Paul Russo
PURPOSE: Tumor size and stage are important prognostic parameters in renal cell carcinoma. While pathological stage T1 and T2 are defined by size alone, the presence of certain intrinsic features can up stage a tumor to pathological stage T3a regardless of size. We investigate the effect of pathological tumor stage on the relationship between tumor size and risk of disease recurrence. MATERIALS AND METHODS: Data were reviewed on patients who underwent nephrectomy at our institution between 2006 and 2013 to identify all those with pathological stage T1, T2 and T3a tumors...
August 2015: Journal of Urology
keyword
keyword
48918
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"